Ireland
--:--IST
Latest
Clinical Trials in the USA / NCT07860905
Recruiting Observational

A Study to Test the Repeatability and Reproducibility in Rod Intercept Time Within the AdaptDx Pro in Healthy Subjects With Normal Vision (FlashForward)

NCT07860905 · tracked via the Priya Life Science USA tracker
Sponsor
AdaptDx, Inc
Phase
Observational
Started
2026-09-18
Last updated
2026-10-06

Condition(s) studied

No Disease

Investigational drug(s) / intervention(s)

AdaptDx Pro

AdaptDx Pro: The AdaptDx device measures changes in dark adaptation via rod intercept time.

Study summary

The purpose of this study is to test the repeatability and reproducibility in Rod Intercept (RI) time with two AdaptDx Pro devices in healthy subjects with normal vision.

Eligibility

Sex
ALL
Min age
22 Years
Max age
49 Years
Healthy volunteers
Accepted
Inclusion Criteria (each eye qualifies for the study independently): 1. Male or female between the ages of 22 and 49 (inclusive) at Visit 1 2. ETDRS BCVA letter score of 85 (Snellen equivalent of 20/20) or better at Visit 1 3. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study 4. Informed of the nature of this study and has provided written informed consent in accordance with institutional, local and national regulatory guidelines Exclusion Criteria (each eye qualifies for the study independently): 1. Unable to follow simple instructions, operate a response button or maintain attention for 20 minutes 2. Diagnosis or history of any ocular disease or disorder 3. Serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study 4. Presence of or history of malignancy within the past year of Visit 1 other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ 5. Is non-ambulatory 6. History of drug, alcohol or substance abuse within 3 months prior to Visit 1 7. Has received an investigational drug or treatment with an investigational device within 3 months prior to Visit 1 8. In the opinion of the Investigator, is unlikely to comply with the study protocol

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Pacific NorthWest Retina (Silverdale) Silverdale Washington Recruiting

More AdaptDx, Inc. trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07860905 on ClinicalTrials.gov ↗ ← All trials in the USA